National Brain Tumor Society (NBTS) 2015 MEDIA KIT Table of Contents About National Brain Tumor Society ...................................................p. 3 About Brain Tumors ..............................................................................p. 8 Media Contact Info & Links ...................................................................p. 11 www.braintumor.org 2 About National Brain Tumor Society www.braintumor.org 3 About the National Brain Tumor Society National Brain Tumor Society’s mission is to find better treatments and ultimately a cure for brain tumors. As the leader in the fight against brain tumors, our strategic initiatives and funded programs aim to improve an understanding of brain tumors to transform research findings into new and more effective treatments, as quickly as possible. To achieve these goals, we foster collaboration with leaders across academia, government, and the private sector to drive systemic change within all facets of the drug discovery and development landscape. Through funded research and public policy initiatives, we strive to address all of the obstacles to getting new and more effective treatments to patients through an integrated approach; from the very first phases of basic research to the clinical trial and FDA approval process. The cumulative effort seeks optimize the entire brain tumor research and development system; to make it a friendlier environment for scientists working in labs to move discoveries to Industry, for industry to more efficiently finish the pre-clinical work and take promising potential treatments into clinical trials earlier; and, finally, for companies to have better pathways and mechanisms at their disposal to speed approval for brain tumor drugs. This will save money, time, and most importantly, lives. Our Programs Clinical Trial Endpoints Initiative – This initiative works with the U.S. Food & Drug Administration (FDA) to recommend alternative (and additional) clinical trial endpoints to accelerate the pace of development for drugs, which will provide clinical benefits to brain tumor patients. Defeat GBM Research Collaborative – Our largest and boldest program to date, this initiative aims to double the five-year survival rate of glioblastoma multiforme (GBM) patients in just five (5) years, through robust research collaborations and a novel scientific construct. GBM is the deadliest form of brain cancer. Oligodendroglioma Research Fund – This program aims to better understand the origins of growth for oligodendroglioma, a rare but deadly brain tumor, and apply these findings to advance the discovery and development of new treatments. Pediatric Initiatives – These programs seek to address the interrelated barriers to pre-clinical research and investment in drug development, as well as identify treatment options, which are safer and minimize long-term side effects on pediatric brain tumor patients. Pediatric brain tumors are the most prevalent form of cancer in children and young adults under the age of 19, and the leading cause of death by disease in children under the age of 14. National Brain Tumor Society is the largest nonprofit dedicated to the brain tumor community in the United States. And a Charity Navigator Four-Star designated nonprofit. www.braintumor.org 4 NBTS EXECUTIVE STAFF SALLY DAVIS Chief Executive Officer Sally Davis joined the National Brain Tumor Society as its Chief Executive Officer in 2014. In this role, she will lead the Organization’s operations to achieve its strategic goals through targeted research programs, key public policy initiatives, and financial growth. Prior to joining the National Brain Tumor Society, she was the National Vice President, Development and Foundations for the Boys & Girls Clubs of America. Ms. Davis has more than 20 years of professional experience across both the public and private sector in academia, insurance, and the pharmaceutical industry. She is also the recipient of the Womenetics POW Award, and the WNBA’s ATL Dream Inspiring Women Award. Ms. Davis holds a Bachelor’s and Master’s from Drake University. DAVID F. ARONS, JD Chief Public Policy and Advocacy Officer David Arons is the Senior Director of Public Policy of the National Brain Tumor Society. In this role, he directs the Organization’s federal and state public policy efforts and nationwide advocacy program. He previously served as the Director of Government Relations for the American Cancer Society. He is the author of several books, including Power in Policy: A Funder’s Guide to Advocacy and Civic Participation, Strengthening Nonprofit Advocacy, and A Voice for Nonprofits and serves on the National Cancer Institute, NIH Director’s Consumer Liaison Group JAMES CHARNLEY Chief Financial Officer James Charnley is the Chief Financial Officer of the National Brain Tumor Society. He joined the Organization in 2012, and effectively manages the accounting, financial planning, information systems, and human resource operations. He has managed the finance and operations for several social justice, commercial, and financial organizations including Benevolent Fraternity of Unitarian Churches and SCM Community Transportation. www.braintumor.org 5 SAMANTHA MASTERSON Chief Advancement Officer Samantha (Samm) Masterson is National Brain Tumor Society’s Chief Advancement Officer. In this role, Ms. Masterson works directly with the Chief Executive Officer to provide vision and leadership to National Brain Tumor Society’s philanthropy programs, comprising: major gifts, annual and planned giving, and foundation and corporate relations, including cause marketing. Ms. Masterson is a proven fundraiser, community builder, and manager of human capital. Previously, she served in leadership, development, and marketing communications positions for prominent for-profit and non-profit organizations, such as the American Liver Society The TJX Companies, March of Dimes, and Alternatives Unlimited, Inc. • MARYANN MORGAN Chief of Staff Maryann Morgan joined the National Brain Tumor Society in 2015 as Chief of Staff. Reporting directly to the Chief Executive Officer, Maryann is responsible for overseeing the operational, administrative, and support functions of the organization, including IT/IS, human resources, as well as office and facilities management. Additionally, Maryann provides strategic leadership and executive management of the organization’s strategic planning process. Maryann is a certified project management professional with expertise in project delivery, organizational leadership, executive and Board communications, and personnel management. Prior to joining the National Brain Tumor Society, Maryann served as Executive and Project Leader to the Office of the President and Office of Institutional Advancement and Marketing Communications at Morehouse School of Medicine. CARRIE TREADWELL Chief Research Officer Carrie Treadwell joined the Organization in 1998 and serves as the Senior Director of Research at the National Brain Tumor Society, as well as Managing Director of the Defeat GBM Research Collaborative, a subsidiary of the Organization. In these roles, she interacts with leading researchers and institutions to guide the development and success of key research initiatives including overseeing the Organization’s grant process. She also serves as a patient advocate for the National Cancer Institute’s Brain Tumor SPORE Program. www.braintumor.org 6 NBTS BOARD OF DIRECTORS Officers Michael J. Nathanson, JD, LLM – Chairman Cord Schlobohm, DMD – Vice Chair Michael Corkin – Treasurer Sarah Durham – Clerk Members Jeffrey Kolodin, Chairman Emeritus Kristen Campana, Esq. Michael Durbin John Frishkopf Richard Genderson Ken Grey Sheila Killeen Chandri Navarro, Esq. Susan Pannullo, MD Alison Ross, Esq. Stephen T. Sadler, JD Rabbi Eric B. Wisnia Honorary Board Members G. Bonnie Feldman Steve Karol Scott Memmott, Esq. Charles B. Wilson, MD www.braintumor.org 7 About Brain Tumors www.braintumor.org 8 Brain Tumors By The Numbers QUICK FACTS § § § § 688,096 Americans are living with a brain tumor. o 550,042 tumors are benign. o 138,054 tumors are malignant. An estimated 68,470 people will receive primary brain tumor diagnoses this year. o 45,300 will be benign. o 23,180 will be malignant. § Male: 55.2% § Female: 44.8% The average survival rate for all malignant brain tumor patients is only 34.2%. o Male: 32.6% o Female: 44.8% o For the most common form of primary malignant brain tumors, glioblastoma multiforme, the five-year relative survival rate is only approximately 5% - 10%, with most patients dying within 15 months. An estimated 13,770 people will die from malignant brain tumors (brain cancer) this year. BRAIN TUMORS IN ADULTS § The most prevalent brain tumor types in adults: o Gliomas, such as glioblastoma multiforme, ependymomas, astrocytomas, and oligodendrogliomas o Meningiomas BRAIN TUMORS IN CHILDREN § § § § § § § An estimated 28,000 children in the U.S. are living with a brain tumor. An estimated 4,620 new cases of childhood and adolescent primary malignant and nonmalignant brain and CNS tumors are expected to be diagnosed in 2015. Pediatric brain tumors are the most prevalent form of childhood cancer in kids under 19. The average survival rate for all children with malignant brain tumors is 66%. Brain tumors are the leading cause of cancer-related deaths in children under 14, and the second leading cause of cancer-related deaths in children and young adults under 20. It is estimated that, in 2009, a total of 47,631.5 years of potential life were lost due to brain tumors in children 0-19 years old. The most prevalent brain tumor types in children: o Astrocytoma o Medulloblastoma o Ependymoma (cont.) www.braintumor.org 9 Brain Tumors By The Numbers (cont.) ADDITIONAL NOTES § More than any other cancer, brain tumors can have lasting and life-altering physical, cognitive, and psychological impacts on a patient’s life. o This means malignant brain tumors can often be described as equal parts neurological disease and deadly cancer. § Even benign brain tumors can be deadly if they interfere with portions of the brain responsible for vital bodily functions. § There are more than 120 different types of brain tumors, many with their own multitude of subtypes. § Despite the amount of brain tumors, and their devastating prognosis, there have only been four (4) FDA approved drugs to treat brain tumors. o For many tumor types, surgery and radiation remain the standard of care. o There has never been a drug developed and approved specifically for pediatric brain tumors. o The four approved therapies for brain tumors have provided only incremental improvements to patient survival, and mortality rates remain little changed over the past 30 years. § Between 1998 and 2014, there were 78 investigational brain tumor drugs that entered the clinical trial evaluation process. 75 failed, and only three (3) were approved (one conditionally). That is a 25:1 failure ratio in developing new brain tumor treatments over the past two decades. § Brain tumors have the highest per-patient initial cost of care for any cancer group, with an annualized mean net costs of care in 2010 US dollars at well over $100,000. § In addition to primary brain tumors, each year in the United States and estimated 100,000 – 170,000 individual will be diagnosed with a secondary, or metastatic, brain tumor. o Five to 25 percent of cancer patients will develop metastases in the brain. o Many different cancer types often metastasize to the brain, including: § Breast cancer § Kidney cancer § Leukemia § Lung cancer § Lymphoma § Melanoma (where nearly 50% of cases will metastasize to the brain) www.braintumor.org 10 Media Contacts & Links www.braintumor.org 11 Media Contacts & Links CONTACTS: Tom Halkin Senior Manager of Communications National Brain Tumor Society thalkin@braintumor.org 617.393.2849 Caitlin Andrews Policy Resolution Group Caitlin.Andrews@policyres.com 202.828.7637 LINKS: National Brain Tumor Society Homepage: www.braintumor.org The Grey Soirée Website: www.braintumor.org/dcgala Frankly Speaking About Brain Tumors: www.braintumor.org/brain-tumor-information Central Brain Tumor Registry of the United States: www.cbtrus.org National Cancer Institute Brain Tumor Page: www.cancer.gov/cancertopics/types/brain Brain Tumor Surveillance, Epidemiology & End Results: seer.cancer.gov/statfacts/html/brain.html www.braintumor.org 12
© Copyright 2024